Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) announced the initiation of process development and intermediate scale-up activities for A83B4C63, the active pharmaceutical ingredient in its proprietary drug candidate ONC010. The work represents a key milestone in the company’s chemistry, manufacturing and controls (CMC) strategy as it advances toward IND-enabling studies and planning for first-in-human clinical evaluation.
Onco said the program will focus on optimizing synthetic processes, improving yield and reproducibility and scaling production of key intermediates required for downstream manufacturing and formulation. The effort will be conducted in collaboration with Dalton Pharma Services and is intended to establish a robust, scalable manufacturing process capable of supporting continued preclinical development, regulatory readiness and future clinical supply requirements.
This development is critical for Onco-Innovations as it moves closer to clinical trials for ONC010, a drug candidate targeting solid tumours. The company has secured an exclusive worldwide license to patented technology that targets solid tumours, and the advancement of manufacturing process development is seen as a de-risking step that could accelerate the timeline to first-in-human studies. By partnering with Dalton Pharma Services, a contract development and manufacturing organization, Onco aims to leverage specialized expertise to ensure the manufacturing process meets regulatory standards for clinical supply.
For investors and the oncology community, the news signals that Onco-Innovations is transitioning from early-stage research into a more mature development phase. The initiation of scale-up activities often precedes key regulatory filings, such as an Investigational New Drug (IND) application with the U.S. Food and Drug Administration. A robust manufacturing process is a prerequisite for clinical trials, as it ensures consistent drug quality and supply. The company’s focus on optimizing yield and reproducibility could also have long-term implications for cost of goods and commercial viability if the drug is eventually approved.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Its mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The full press release is available at https://nnw.fm/kfFWv. For more information about the company, visit https://oncoinnovations.com/.
The announcement comes amid growing interest in targeted cancer therapies, and Onco’s progress in manufacturing process development may help position the company to advance its pipeline toward clinical testing. As the company works toward IND-enabling studies, the successful scale-up of ONC010’s manufacturing process will be closely watched by stakeholders.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Onco-Innovations Advances Manufacturing Process for Cancer Drug Candidate ONC010.